Emerging drugs for the prevention of migraine

References

• Lipton R, Stewart W, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41(7):646–657.
   PubMed Web of Science ®Google Scholar
• Vos T, Lim SS, Abbafati C, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–1222.
   PubMed Web of Science ®Google Scholar
• Migraine — level 4 cause [Internet]. Institute for health metrics and evaluation. 2021 [cited 2021 Mar 31]. Available from: http://www.healthdata.org/results/gbd_summaries/2019/migraine-level-4-cause
   Google Scholar
• Linde M, Gustavsson A, Stovner L, et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol. 2011;19(5):703–711.
   PubMed Web of Science ®Google Scholar
• Bigal M, Lipton R. Clinical course in migraine: conceptualizing migraine transformation. Neurology. 2008;71(11):848–855.
   PubMed Web of Science ®Google Scholar
• Natoli J, Manack A, Dean B, et al. Global prevalence of chronic migraine: a systematic review. Cephalalgia. 2010;30(5):599–609.
   PubMed Web of Science ®Google Scholar
• Goadsby P, Holland P, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.
   PubMed Web of Science ®Google Scholar
• Ferrari M, Roon K, Lipton R, et al. Oral triptans (serotonin 5-HT 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358(9294):1668–1675.
   PubMed Web of Science ®Google Scholar
• Hepp Z, Bloudek L, Varon S. Systematic review of migraine prophylaxis adherence and persistence. J Managed Care Pharm. 2014;20(1):22–33.
   Google Scholar
• Aurora S, Dodick D, Turkel C, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia. 2010;30(7):793–803.
   PubMed Web of Science ®Google Scholar
• Diener H, Dodick D, Aurora S, et al. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia. 2010;30(7):804–814.
   PubMed Web of Science ®Google Scholar
• Ho T, Edvinsson L, Goadsby P. CGRP and its receptors provide new insights into migraine pathophysiology. Nat Rev Neurol. 2010;6(10):573–582.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Silberstein SD, Bigal ME, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA. 2018;319(19):1999–2008.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–2122.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Reuter U, Hallström Y, et al. A controlled trial of erenumab for episodic migraine. N Engl J Med. 2017;377(22):2123–2132.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;38(6):1026–1037.
   PubMed Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434.
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080–1088.
   PubMed Web of Science ®Google Scholar
• Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211–e2221.
   PubMed Web of Science ®Google Scholar
• Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442–1454.
   PubMed Web of Science ®Google Scholar
• Ashina M, Saper J, Cady R, et al. Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia. 2020;40(3):241–254.
   PubMed Web of Science ®Google Scholar
• Lipton R, Goadsby P, Smith J, et al. Efficacy and safety of eptinezumab in patients with chronic migraine. Neurology. 2020;94(13):e1365–e1377.
   PubMed Web of Science ®Google Scholar
• Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients – a review of pros and cons. J Headache Pain. 2017 Sep 25;18(1):96.
   PubMed Web of Science ®Google Scholar
• Do T, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? J Headache Pain. 2019;20:1.
   PubMed Web of Science ®Google Scholar
• Ornello R, Casalena A, Frattale I, et al. Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain. 2020;21(1):1.
   PubMed Web of Science ®Google Scholar
• MaassenVanDenBrink A, Meijer J, Villalón C, et al. Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci. 2016;37(9):779–788.
   PubMed Web of Science ®Google Scholar
• Loder E, Burch R. Who should try new antibody treatments for migraine? JAMA Neurol. 2018;75(9):1039.
   PubMed Web of Science ®Google Scholar
• Cohen J, Ning X, Kessler Y, et al. Immunogenicity of biologic therapies for migraine: a review of current evidence. J Headache Pain. 2021;22(1):1.
   PubMed Web of Science ®Google Scholar
• Ashina M, Goadsby P, Reuter U, et al. Long‐term efficacy and safety of erenumab in migraine prevention: results from a 5‐year, open‐label treatment phase of a randomized clinical trial. Eur J Neurol. 2021;28(5):1716–1725.
   PubMed Web of Science ®Google Scholar
• Reuter U, Goadsby PJ, Lanteri-Minet M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet. 2018;392(10161):2280–2287.
   PubMed Web of Science ®Google Scholar
• Ferrari M, Diener H, Ning X, et al. Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet. 2019;394(10203):1030–1040.
   PubMed Web of Science ®Google Scholar
• Mulleners W, Kim B, Láinez M, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19(10):814–825.
   PubMed Web of Science ®Google Scholar
• Sacco S, Bendtsen L, Ashina M, et al. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain. 2019;20:1.
   PubMed Web of Science ®Google Scholar
• Croop R, Lipton R, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51–60.
   PubMed Web of Science ®Google Scholar
• NURTEC ODT (Rimegepant) prescribing information. [cited 2021 Jan 21]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212728s000lbl.pdf
   Google Scholar
• Goadsby P, Dodick D, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020;19(9):727–737.
   PubMed Web of Science ®Google Scholar
• AIlani J, Lipton RB, Goadsby PJ, et al. Atogepant significantly reduces mean monthly migraine days in the phase 3 trial (ADVANCE) for the prevention of migraine. Cephalalgia. 2020;40(1S):14–15.
   Google Scholar
• Miyata A, Arimura A, Dahl RR, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun. 1989;164(1):567–574.
   PubMed Web of Science ®Google Scholar
• Vaudry D, Falluel-Morel A, Bourgault S, et al. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev. 2009;61(3):283–357.
   PubMed Web of Science ®Google Scholar
• Arimura A, Somogyvári-Vigh A, Miyata A, et al. Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology. 1991;129(5):2787–2789.
   PubMed Web of Science ®Google Scholar
• Harmar AJ, Fahrenkrug J, Gozes I, et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol. 2012;166(1):4–17.
   PubMed Web of Science ®Google Scholar
• Edvinsson L, Tajti J, Szalárdy L, et al. PACAP and its role in primary headaches. J Headache Pain. 2018;19(1):21.
   PubMedGoogle Scholar
• Palkovits M, Somogyvári-Vigh A, Arimura A. Concentrations of pituitary adenylate cyclase activating polypeptide (PACAP) in human brain nuclei. Brain Res. 1995;699(1):116–120.
   PubMed Web of Science ®Google Scholar
• Fahrenkrug J, Hannibal J. Localisation of the neuropeptide PACAP and its receptors in the rat parathyroid and thyroid glands. Gen Comp Endocrinol. 2011;171(1):105–113.
   PubMed Web of Science ®Google Scholar
• Köves K, Kántor O, Scammell J, et al. PACAP colocalizes with luteinizing and follicle-stimulating hormone immunoreactivities in the anterior lobe of the pituitary gland. Peptides. 1998;19(6):1069–1072.
   PubMed Web of Science ®Google Scholar
• Moody T, Ito T, Osefo N, et al. VIP and PACAP: recent insights into their functions/roles in physiology and disease from molecular and genetic studies. Curr Opin Endocrinol Diabetes Obes. 2011;18(1):61–67.
   PubMedGoogle Scholar
• Barberi M, Muciaccia B, Morelli M, et al. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary. Reproduction. 2007;134(2):281–292.
   PubMed Web of Science ®Google Scholar
• Dickson L, Finlayson K. VPAC and PAC receptors: from ligands to function. Pharmacol Ther. 2009;121(3):294–316.
   PubMed Web of Science ®Google Scholar
• Banks WA, Kastin AJ, Komaki G, et al. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. J Pharmacol Exp Ther. 1993;267(2):690–696.
   PubMed Web of Science ®Google Scholar
• Tajti J, Uddman R, Edvinsson L. Neuropeptide localization in the ‘migraine generator’ region of the human brainstem. Cephalalgia. 2001;21(2):96–101.
   PubMed Web of Science ®Google Scholar
• Knutsson M, Edvinsson L. Distribution of mRNA for VIP and PACAP receptors in human cerebral arteries and cranial ganglia. NeuroReport. 2002;13(4):507–509.
   PubMed Web of Science ®Google Scholar
• Robert C, Bourgeais L, Arreto CD, et al. Paraventricular hypothalamic regulation of trigeminovascular mechanisms involved in headaches. J Neurosci. 2013;33(20):8827–8840.
   PubMed Web of Science ®Google Scholar
• Eftekhari S, Salvatore C, Johansson S, et al. Localization of CGRP, CGRP receptor, PACAP and glutamate in trigeminal ganglion. Relation to the blood–brain barrier. Brain Res. 2015;1600:93–109.
   PubMed Web of Science ®Google Scholar
• Rubio-Beltrán E, Correnti E, Deen M, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018; 19(1). DOI: https://doi.org/10.1186/s10194-018-0893-8
   Google Scholar
• Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine. Sci Transl Med. 2015;7:1–11.
   Web of Science ®Google Scholar
• Birk S, Sitarz JT, Petersen KA, et al. The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept. 2007;140(3):185–191.
   PubMedGoogle Scholar
• Schytz HW, Birk S, Wienecke T, et al. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009;132(1):16–25.
   PubMedGoogle Scholar
• Amin FM, Asghar MS, Guo S, et al. Headache and prolonged dilatation of the middle meningeal artery by PACAP38 in healthy volunteers. Cephalalgia. 2012 Jan;32(2):140–149.
   PubMed Web of Science ®Google Scholar
• Amin FM, Hougaard A, Schytz HW, et al. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain. 2014;137(3):779–794.
   PubMedGoogle Scholar
• Amin FM, Hougaard A, Magon S, et al. Change in brain network connectivity during PACAP38-induced migraine attacks A resting-state functional MRI study. Neurology. 2016;86(2):180–187.
   PubMed Web of Science ®Google Scholar
• Tuka B, Helyes Z, Markovics A, et al. Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia. 2013;33(13):1085–1095.
   PubMed Web of Science ®Google Scholar
• Zagami A, Edvinsson L, Goadsby P. Pituitary adenylate cyclase activating polypeptide and migraine. Ann Clin Transl Neurol. 2014;1(12):1036–1040.
   PubMed Web of Science ®Google Scholar
• Ashina M, Dolezil D, Bonner JH. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia. 2021;41(1):33–44.
   PubMed Web of Science ®Google Scholar
• Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and g protein-coupled receptors that regulate feeding behavior. Cell. 1998;92(4):573–585.
   PubMed Web of Science ®Google Scholar
• Holland PR, Holland PR. Biology of neuropeptides: orexinergic involvement in primary headache disorders. Headache. 2017;57(Suppl 2):76–88.
   PubMedGoogle Scholar
• Bertels Z, Pradhan A. Emerging treatment targets for migraine and other headaches. Headache. 2019;59(S2):50–65.
   PubMedGoogle Scholar
• Ferguson AV, Samson WK. The orexin/hypocretin system: a critical regulator of neuroendocrine and autonomic function. Front Neuroendocrinol. 2003;24(3):141–150.
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Rainero I, Coppola F, et al. Involvement of corticotrophin-releasing factor and orexin-a in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid. Cephalalgia. 2008;28(7):714–722.
   PubMed Web of Science ®Google Scholar
• Dahmen N, Kasten M, Wieczorek S, et al. Increased frequency of migraine in narcoleptic patients: a confirmatory study. Cephalalgia. 2003;23(1):14–19.
   PubMed Web of Science ®Google Scholar
• Rasmussen B, Jensen R, Schroll M, et al. Epidemiology of headache in a general population—A prevalence study. J Clin Epidemiol. 1991;44(11):1147–1157.
   PubMed Web of Science ®Google Scholar
• Breslau N, Davis GC, Andreski P. Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults. Psychiatry Res. 1991;37:11–23.
   PubMed Web of Science ®Google Scholar
• Stewart WF, Wood C, Reed ML, et al. Cumulative lifetime migraine incidence in women and men. Cephalalgia. 2008;28:1170–1178.
   PubMed Web of Science ®Google Scholar
• Bartsch T, Levy MJ, Knight YE, et al. Differential modulation of nociceptive dural input to [hypocretin] orexin A and B receptor activation in the posterior hypothalamic area. Pain. 2004;109(3):367–378.
   PubMed Web of Science ®Google Scholar
• Holland PR, Akerman S, Goadsby PJ, Holland PR, Akerman S, Goadsby PJ. Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther. 2005;315(3):1380–1385.
   PubMed Web of Science ®Google Scholar
• Holland PR, Akerman S, Goadsby PJ, Holland PR, Akerman S, Goadsby PJ. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci. 2006;24(10):2825–2833.
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Supronsinchai W, Akerman S, et al. Evidence for orexinergic mechanisms in migraine. Neurobiol Dis. 2015;74:137–143.
   PubMed Web of Science ®Google Scholar
• Chabi A, Zhang Y, Jackson S, et al. Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia. 2015;35(5):379–388.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. Putting migraine to sleep: rexants as a preventive strategy. Cephalalgia. 2015;35(5):377–378.
   PubMed Web of Science ®Google Scholar
• Kew J, Kemp J. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl). 2005;179(1):4–29.
   PubMed Web of Science ®Google Scholar
• Bowes M, Panesar M, Gentry C, et al. Anti-hyperalgesic effects of the novel metabotropic glutamate receptor 5 antagonist, 2-methyl-6-(phenylethynyl)-pyridine, in rat models of inflammatory pain. Br J Pharmacol. 1999;126:250P.
   Web of Science ®Google Scholar
• Walker K, Reeve A, Bowes M, et al. mGlu5 receptors and nociceptive function II. mGlu5 receptors functionally expressed on peripheral sensory neurones mediate inflammatory hyperalgesia. Neuropharmacology. 2001;40:10–19.
   PubMed Web of Science ®Google Scholar
• Walker K, Bowes M, Panesar M, et al. Metabotropic glutamate receptor subtype 5 (mGlu5) and nociceptive function I. Selective blockade of mGlu5 receptors in models of acute, persistent and chronic pain. Neuropharmacology. 2001;40(1);1-9.
   Web of Science ®Google Scholar
• Niswender C, Conn P. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol. 2010;50(1):295–322.
   PubMedGoogle Scholar
• Ferrari MD, Odink J, Bos KD, et al. Neuroexcitatory plasma amino acids are elevated in migraine. Neurology. 1990;40:1582–1586.
   PubMed Web of Science ®Google Scholar
• Campos F, Sobrino T, Perez-Mato M, et al. Glutamate oxaloacetate transaminase: a new key in the dysregulation of glutamate in migraine patients. Cephalalgia. 2013;33:1148–1154.
   PubMed Web of Science ®Google Scholar
• Martinez F, Castillo J, Rodriguez JR, et al. Neuroexcitatory amino acid levels in plasma and cerebrospinal fluid during migraine attacks. Cephalalgia. 1993;13:89–93.
   PubMed Web of Science ®Google Scholar
• Peres MF, Zukerman E, Senne Soares CA, et al. Cerebrospinal fluid glutamate levels in chronic migraine. Cephalalgia. 2004;24:735–739.
   PubMed Web of Science ®Google Scholar
• Rajda C, Tajti J, Komoróczy R, et al. Amino acids in the saliva of patients with migraine. Headache. 1999;39:644–649.
   PubMedGoogle Scholar
• Nam JH, Lee HS, Kim J, et al. Salivary glutamate is elevated in individuals with chronic migraine. Cephalalgia. 2018;38(8):1485–1492.
   PubMed Web of Science ®Google Scholar
• Baad-Hansen L, Cairns B, Ernberg M, et al. Effect of systemic monosodium glutamate (MSG) on headache and pericranial muscle sensitivity. Cephalalgia. 2010;30:68–76.
   PubMed Web of Science ®Google Scholar
• Yang WH, Drouin MA, Herbert M, et al. The monosodium glutamate symptom complex: assessment in a double-blind, placebo-controlled, randomized study. J Allergy Clin Immunol. 1997;99:757–762.
   PubMed Web of Science ®Google Scholar
• Bhave G, Karim F, Carlton SM, et al. Peripheral group I metabotropic glutamate receptors modulate nociception in mice. Nat Neurosci. 2001;4:417–423.
   PubMed Web of Science ®Google Scholar
• Li B, Lu L, Tan X, et al. Peripheral metabotropic glutamate receptor subtype 5 contributes to inflammation-induced hypersensitivity of the rat temporomandibular joint. J Mol Neurosci. 2013;51:710–718.
   PubMed Web of Science ®Google Scholar
• Waung MW, Akerman S, Wakefield M, et al. Metabotropic glutamate receptor 5: a target for migraine therapy. Ann Clin Transl Neurol. 2016;3:560–571.
   PubMed Web of Science ®Google Scholar
• Hoffmann J, Charles A. Glutamate and its receptors as therapeutic targets for migraine. Neurotherapeutics. 2018;15:361–370.
   PubMed Web of Science ®Google Scholar
• Kawasaki Y, Kohno T, Zhuang Z-Y, et al. Ionotropic and metabotropic receptors, protein kinase A, protein kinase C, and Src contribute to C-fiber-induced ERK activation and cAMP response element-binding protein phosphorylation in dorsal horn neurons, leading to central sensitization. J Neurosci. 2004;24:8310–8321.
   PubMed Web of Science ®Google Scholar
• Niu Y, Zeng X, Zhao L, et al. Metabotropic glutamate receptor 5 regulates synaptic plasticity in a chronic migraine rat model through the PKC/NR2B signal. J Headache Pain. 2020;21:1.
   PubMed Web of Science ®Google Scholar
• Rascol O, Fox S, Gasparini F, et al. Use of metabotropic glutamate 5‐receptor antagonists for treatment of levodopa‐induced dyskinesias. Parkinsonism Relat Disord. 2014;20:947–956.
   PubMed Web of Science ®Google Scholar
• Bryan NS, Bian K, Murad F. Discovery of the nitric oxide signaling pathway and targets for drug development. Front Biosci (Landmark Ed). 2009;14:1‐18.
   Web of Science ®Google Scholar
• Moncada S, Higgs EA. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol. 2006;147(Suppl. 1):S193‐ S201.
   PubMedGoogle Scholar
• Pradhan AA, Bertels Z, Akerman S. Targeted Nitric oxide synthase inhibitors for migraine. Neurotherapeutics. 2018;15(2):391–401.
   PubMed Web of Science ®Google Scholar
• Sicuteri F, Del Bene E, Poggioni M, et al. Unmasking latent dysnociception in healthy subjects. Headache. 1987;27(4):180–185.
   PubMed Web of Science ®Google Scholar
• Akerman S, Karsan N, Bose P, et al. Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity. Brain. 2019;142(1):103–119.
   PubMedGoogle Scholar
• Ramachandran R, Ploug K, Hay-Schmidt A, et al. Nitric oxide synthase (NOS) in the trigeminal vascular system and other brain structures related to pain in rats. Neurosci Lett. 2010;484(3):192–196.
   PubMed Web of Science ®Google Scholar
• Dieterle A, Fischer M, Link A, et al. Increase in CGRP- and nNOS-immunoreactive neurons in the rat trigeminal ganglion after infusion of an NO donor. Cephalalgia. 2010;31(1):31–42.
   PubMed Web of Science ®Google Scholar
• Pardutz A, Krizbai I, Multon S, et al. Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalis. NeuroReport. 2000;11(14):3071–3075.
   PubMed Web of Science ®Google Scholar
• Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109‐142.
   PubMed Web of Science ®Google Scholar
• Palmer JE, Guillard FL, Laurijssens BE, et al. randomised, single-blind, placebo-controlled, adaptive clinical trial of GW274150, a selective iNOS inhibitor, in the treatment of acute migraine. Cephalalgia. 2009;29:124.
   Google Scholar
• Høivik H, Laurijssens B, Harnisch L, et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia. 2010;30(12):1458–1467.
   PubMed Web of Science ®Google Scholar
• Akerman S, Williamson D, Kaube H, et al. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol. 2002;137(1):62–68.
   PubMed Web of Science ®Google Scholar
• Bhatt D, Gupta S, Jansen-Olesen I, et al. NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models. Cephalalgia. 2012;33(2):87–100.
   PubMed Web of Science ®Google Scholar
• De Felice M, Ossipov M, Wang R, et al. Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers. Brain. 2010;133(8):2475–2488.
   PubMedGoogle Scholar
• Medve RA, Lategan TW. A phase 2 multicenter, randomized, double-blind, parallel-group, placebo-controlled study of NXN-188 dihydrochloride in acute migraine without aura [abstract 190]. Presented at the 2nd European headache and migraine trust international congress 2010. Nice, France, 28–31 October 2010. J Headache Pain. 2010;11:38.
   Web of Science ®Google Scholar
• Hougaard A, Hauge AW, Guo S, et al. The nitric oxide synthase inhibitor and serotonin-receptor agonist NXN-188 during the aura phase of migraine with aura: a randomized, double-blind, placebo-controlled cross-over study. Scand J Pain. 2013;4(1):48–52.
   PubMedGoogle Scholar
• Hansen JM, Hauge AW, Olesen J, et al. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30:1179–1186.
   PubMed Web of Science ®Google Scholar
• Christopoulos A, Christopoulos G, Morfis M, et al. Novel receptor partners and function of receptor activity-modifying proteins. J Biol Chem. 2003;278(5):3293–3297.
   PubMed Web of Science ®Google Scholar
• Guo S, Vollesen AL, Hansen YB, et al. Part II: biochemical changes after pituitary adenylate cyclase‐activating polypeptide‐38 infusion in migraine patients. Cephalalgia. 2017;37:136‐147.
   Web of Science ®Google Scholar